Clinical trials: Patients With Major Depressive Disorder
Major Depressive Disorder
Omega-3 Fatty Acids as Adjunct Treatment for Major Depressive Disorder
The primary objective of the study was to determine the effects of 10-week adjunctive supplementation with 2 doses of LCn-3 fatty acids (fish oil) on cortical functional activity and biochemistry in adolescents with MDD.
- Trial name
- NCT00511810
- Testing
- Low Dose Fish Oil, High Dose Fish Oil
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Cincinnati
Major Depressive Disorder
Escitalopram Combination Comparison Study for Adult Patients With Major Depressive Disorder
The purpose of this study is to evaluate the effectiveness, safety and tolerability of an escitalopram combination treatment compared to single treatments, and to placebo in patients with major depressive disorder.
- Trial name
- NCT00239954
- Testing
- Escitalopram
- Where
- 4 sites in United States
- Sponsor
- Pharmacology Research Institute
Bipolar II Disorder, Major Depressive Episode
Open-Label Study of Geodon in Non-Rapid Cycling Bipolar II Patients With Major Depression
The purpose of this study is to evaluate the antidepressant effectiveness of Geodon for the treatment of patients diagnosed with Bipolar II disorder who are currently experiencing a major depressive episode.
- Trial name
- NCT00237666
- Testing
- Ziprasidone
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- The Medical Research Network
Depression - Major Depressive Disorder, Generalized Anxiety Disorder (GAD)
Microbiota Modulation for Psychiatry Patients
The investigators aim to confirm pilot study findings (REB 119638) on the effects of delayed release apple cider vinegar (drACV).
- Conditions
- Depression - Major Depressive Disorder, Generalized Anxiety Disorder (GAD), Anxiety
- Trial name
- ACV-MTPIES-002 (NCT07899424)
- Testing
- Dietary Supplement: Acetate (Apple Cider Vinegar)
- Volunteers
- 62 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Major Depressive Disorder
Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the Diagnostic and Statistical Manual of Mental Disorders…
- Trial name
- NCT04985942
- Testing
- Lumateperone
- Where
- 54 sites in United States, Bulgaria and 4 more
- Volunteers
- 485 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Major Depressive Disorder, Soft Tissue Discomfort Syndrome
Functional Change and Efficacy of Duloxetine in Patients With Co-Morbid Depression & Soft Tissue Discomfort Syndrome
The objective of this study is to determine the time course of duloxetine efficacy on the symptoms of Major Depressive Disorder (MDD)and on the symptoms of Soft Tissue Discomfort Syndrome(STDS) via use of 24-hour Actigraph™…
- Conditions
- Major Depressive Disorder, Soft Tissue Discomfort Syndrome, Pain
- Trial name
- NCT01035073
- Testing
- Duloxetine
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Pennsylvania
Schizophrenia, Major Depressive Disorder
Clinical Registry of Patients Under Treatment With Atypical Antipsychotics
Antipsychotic drugs are characterized by blocking dopaminergic D2 receptors. They have been found to be effective and safe for the treatment of schizophrenia, bipolar disorders, depressive episodes associated with bipolar…
- Conditions
- Schizophrenia, Major Depressive Disorder, Bipolar Depressive Disorder, Parkinson's Disease With Hallucinations
- Trial name
- NCT02409823
- Testing
- Atypical Antipsychotics
- Volunteers
- 665 people
- Sponsor
- Pontifical Catholic University of Argentina
Depressive Disorder, Major
Trial to Evaluate Efficacy of Pharmacogenetic Information Obtained With NEUROPHARMAGEN in Treatment of MDD Patients
This study evaluates the efficacy of NEUROPHARMAGEN pharmacogenetic test in the selection of the pharmacological treatments for patients with Major Depressive Disorder (MDD), both with and without psychiatric comorbidities.
- Trial name
- NCT02529462
- Testing
- NEUROPHARMAGEN-Guided Treatment, Treatment As Usual
- Where
- 12 sites in Spain
- Volunteers
- 521 people
- Sponsor
- AB Biotics, SA
Major Depressive Disorder
Effect of Physical Activity on Depressive Symptoms With a 5 Month Follow-up
The main objective of this study is to evaluate the effect of a 12 weeks adapted physical activity program (active walking) on depression by analyzing the dynamics of emotional and cognitive functioning.
- Trial name
- 2DPAP (NCT01995422)
- Testing
- Physical activity program
- Where
- France
- Volunteers
- 16 people
- Sponsor
- Laboratory Motricité, Interactions, Performance
Depressive Disorder, Major
A Safety Study in Participants With Major Depressive Disorder
The primary objective of this study is to evaluate the long-term safety and tolerability of LY2216684 administered once daily (QD) in the adjunctive treatment with a selective serotonin reuptake inhibitor (SSRI) for up to…
- Trial name
- NCT01155661
- Testing
- LY2216684 (edivoxetine), SSRI
- Where
- 48 sites in United States, Brazil and 5 more
- Volunteers
- 608 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
Iloperidone Augmentation of SSRIs for Patients With Major Depressive Disorder With Residual Anger and Irritability
Iloperidone is an atypical antipsychotic drug, FDA-approved for the acute treatment of schizophrenia in adults in 2009 (Marino et al., 2010); moreover, some of its pharmacological features seem to be very promising in treating…
- Trial name
- NCT01464229
- Testing
- Iloperidone
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Maurizio Fava, MD
Major Depressive Disorder
Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
The objective of this study is to evaluate the efficacy, safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy (ADT) in patients with MDD
- Trial name
- NCT01715805
- Testing
- Cariprazine, Antidepressant Therapy (ADT)
- Where
- 85 sites in United States, Puerto Rico
- Volunteers
- 1,022 people
- Sponsor
- Forest Laboratories
Major Depressive Disorder
A Study of Fluoxetine in Major Depressive Disorder (MDD) Long-Term Dosing
This study will evaluate the safety and effectiveness of fluoxetine flexible dosing in the treatment of MDD in adult Japanese participants.
- Trial name
- NCT01808651
- Testing
- Fluoxetine
- Where
- 16 sites in Japan
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Depressive Disorder, Major
The Effect of Agomelatine or Fluoxentine on Heart Rate Variability in Patients With Major Depressive Disorder
Phase advance of HRV will be anticipated in agomelatine group. It is anticipated that both agomelatine and floxentine will increase HRV at the end of the treatment.
- Trial name
- NCT00451490
- Testing
- Agomelatine, Fluoxentine
- Where
- Taiwan
- Volunteers
- 24 people
- Sponsor
- National Taiwan University Hospital
Major Depressive Disorder
Psychophysiological Study of Pain Perception in Depressed Patients With Suicidal Risk
Joiner's interpersonal theory of suicide postulates that the wish of death comes from feelings of perceived burdensomeness and thwarted belongingness.
- Trial name
- R2D2 (NCT04461327)
- Testing
- Painful stimulations of major depressive patients, Blood sample, Clinical assessment
- Where
- 2 sites in France
- Volunteers
- 144 people
- Sponsor
- University Hospital, Montpellier
Depressive Disorder, Major
Study of Rapastinel as Monotherapy in Patients With Major Depressive Disorder (MDD)
The study will evaluate the efficacy, safety, and tolerability of 225 milligrams (mg) and 450 milligrams (mg) of Rapastinel, compared to placebo in participants with major depressive disorder (MDD).
- Trial name
- NCT03675776
- Testing
- Rapastinel
- Where
- 23 sites in Hungary, Japan and 3 more
- Volunteers
- 50 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Major Depressive Disorder
5-HTP and Creatine for Depression
This is a three-armed clinical trial examining the effect of 5-hydroxytryptophan and creatine monohydrate as augmenting agents for the treatment of depression.
- Trial name
- NCT04395183
- Testing
- 5-Hydroxytryptophan 100 MG, Creatine monohydrate
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- University of Utah
Depressive Disorder, Major
Interventional Study of Wellbutrin XL in Major Depressive Disorder With Atypical Features
The aims of this study are 1) to examine the clinical utility of bupropion hydrochloride extended release (Wellbutrin XL®) in patients with Major Depressive Disorder (MDD) with atypical features; 2) to evaluate the tolerability…
- Trial name
- WellbutrinXL (NCT01477931)
- Testing
- Bupropion extended release
- Where
- 6 sites in South Korea
- Volunteers
- 50 people
- Sponsor
- Chi-Un Pae
Major Depressive Disorder
Trial of a Positive Psychology Intervention in Major Depressive Disorder
In this study, the investigators will perform an exploratory randomized trial of Positive Psychology (PP). The trial will consist of 50 participants and will compare the impact of a phone-based PP intervention vs.
- Trial name
- HOPE (NCT02004145)
- Testing
- Positive Psychology, Control Condition
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder, Depression
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder
The purpose of this study is to determine if TC-5214 or placebo (a tablet that looks like medicine tablet or capsule, but contains no active medicine) is safe and effective when taken together with another antidepressant.
- Trial name
- NCT01180400
- Testing
- TC-5214
- Where
- 66 sites in Czechia, Estonia and 8 more
- Volunteers
- 295 people
- Sponsor
- AstraZeneca